> In a study of people without known cardiovascular disease, assessing CRP or fibrinogen level in people at intermediate risk for a cardiovascular event could help prevent one additional event over a period of 10 years for every 400 to 500 people screened. Each test costs $60 to $150, and may or may not be covered by health plans. So, given these figures--is screening worthwhile? Abstract | Article
> According to an early analysis of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, a variant in a gene involved with inflammation and the immune response is linked with a decreased risk of lung cancer, supporting the idea that inflammation is associated with lung cancer risk. Press release | Abstract
> The first trial of scans of breast cancer tumor whole genomes as an alternative to single-gene tests aims to help doctors select the right treatment has been carried out. Press release
> Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer. Abstract
> High blood pressure during pregnancy could be a marker for lower IQ for the children. Article
And Finally… Squeezing cells to check for stiffness could differentiate between healthy, malignant and metastatic cells. Article